Reading MTNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MTNB free→Reading MTNB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MTNB free→QuarterlyIQ Insights · MTNB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 2, 2026, Matinas BioPharma Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously reported, on November 18, 2025, Keith Kucinski, Chief Financial Officer of Matinas BioPharma Holdings, Inc. (the “Company”), notified the Company of his intention to resign from his position as Chief Financial Officer, effective January 17, 2026, to pursue other opportunities. On January 22, 2026, the board of directors (the “Board”)…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) and Jerome D. Jabbour, the Company’s Chief Executive Officer, entered into the Third Amendment (the “Amendment”) to the Employment Agreement, between the Company and Mr. Jabbour, dated March 22, 2018 (as previously amended by that certain First Amendment, dated March 3, 2023, an…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 18, 2025, Keith Kucinski, Chief Financial Officer of Matinas BioPharma Holdings, Inc. (the “Company”), notified the Company of his intention to resign from his position as Chief Financial Officer, effective January 17, 2026, to pursue other opportunities. Mr. Kucinski’s resignation was not the result of any disagreement with the Company…
The Exchange Shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act.
Entry into a Material Definitive Agreement. On August 15, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) entered into Warrant Exchange Agreements (the “Exchange Agreements”) with certain holders (the “Exchanging Holders”) of warrants (the “Warrants”) to purchase an aggregate of 466,666 shares the Company’s common stock, par value $0.0001 per share (the “Common Stock”) having a current exercise price of $17.50. The Warrants were issued on April 5, 2024. Pursuant to the Exchange Agreeme…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 23, 2025, Matinas BioPharma Holdings, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved the Company’s 2025 Equity Incentive Plan (the “2025 Plan”). The board of directors of the Company (the “Board”) had previously approved the 2025 Plan on Ap…
Material Modification to Rights of Security Holders. On April 30, 2025, the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) approved and adopted an amendment (the “ Amendment ”) to the Company’s bylaws (the “ Bylaws ”) which reduces the number of shares required to constitute a quorum at a stockholders meeting of the holders of shares of the outstanding capital stock of the Company to provide that stockholders holding one-third of the voting power of t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Employment Agreement Amendments On April 30, 2025, the Board of the Company amended the Employment Agreement of Jerome D. Jabbour, dated May 22, 2018, as previously amended (the “ Jabbour Employment Agreement ”), to provide for a cash retention bonus in the event of a change in control of the Company, as such term is defined in the Jabbour Employme…
Other Events. As previously reported, on February 13, 2025, Matinas BioPharma Holdings, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), an aggregate of 3,300 shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share (the “ Preferred Stock ”) and warrants (the “ Warrants ”…
Unregistered Sales of Equity Securities. The disclosure required by this Item and included in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 13, 2025, Eric Ende informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning as a member of the Board and as Chairman of the Board effective March 14, 2025, due to his other professional obligations. Mr. Ende’s resignation was not the result of a material disagreement or ch…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations. In connection with her resignation, Ms. Giordano also resigned from her positions on the Board’…
Material Modifications to Rights of Security Holders. The disclosure required by this Item and included in
Entry into a Material Definitive Agreement . On February 13, 2025, Matinas BioPharma Holdings, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), an aggregate of 3,300 shares of the Company’s Series C Convertible Preferred Stock, par value $0.0001 per share (the “ Preferred Stock ”…
Unregistered Sales of Equity Securities. The disclosure required by this Item and included in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of the Initial Closing Date, the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company. The Board appointed Dr. Smith to serve as a member of the Board’s Audit and Nominating and Corporate Governance Committees. The Board has determined that Dr. Smith (i) is ind…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 5, 2025, Herbert Conrad informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that he was resigning from the Board effective February 6, 2025, due to retirement. In connection with his resignation, Mr. Conrad also resigned from his positions on the Board’s Audit and Nominating and Corporat…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.